Summary: Proc. Natl. Acad. Sci. USA
Vol. 93, pp. 6814­6818, June 1996
Medical Sciences
Radioimmunotherapy with a 64
Cu-labeled monoclonal antibody:
A comparison with 67
Cu
JUDITH M. CONNETT*, CAROLYN J. ANDERSON, LI-WU GUO*, SALLY W. SCHWARZ, KURT R. ZINN,
BUCK E. ROGERS, BARRY A. SIEGEL§, GORDON W. PHILPOTT*, AND MICHAEL J. WELCH¶
*Department of Surgery and Divisions of Radiation Sciences and §Nuclear Medicine, Washington University School of Medicine. St. Louis, MO 63110; and
University of Missouri Research Reactor, Columbia, MO 65211
Communicated by Alfred P. Wolf, Brookhaven National Laboratory, Upton, NY, March 11, 1996 (received for review October 9, 1995)
ABSTRACT 67
Cu (t1
2
62 h) has demonstrated potential
as a radionuclide for radioimmunotherapy, but limited avail-
ability severely restricts its widespread use. 64
Cu (t1
2

Source: Anderson, Carolyn J. - Department of Molecular Biology and Pharmacology, Washington University in St. Louis

Collections: Biology and Medicine